Detalhe da pesquisa
1.
Venous and Arterial Thrombosis in Patients with VEXAS Syndrome.
Blood
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306657
2.
Spectrum of clonal hematopoiesis in VEXAS syndrome.
Blood
; 142(3): 244-259, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084382
3.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood
; 139(7): 1066-1079, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699595
4.
Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy.
Haematologica
; 109(2): 509-520, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646653
5.
Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
Haematologica
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450522
6.
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299584
7.
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Haematologica
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546692
8.
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
Am J Hematol
; 99(2): 284-299, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950858
9.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Am J Hematol
; 99(2): 193-202, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071734
10.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Am J Hematol
; 99(2): E63-E66, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100217
11.
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Br J Haematol
; 202(2): 279-283, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37144345
12.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Haematologica
; 108(11): 3033-3043, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199125
13.
Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations.
Am J Hematol
; 98(6): 951-964, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36938794
14.
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants.
Am J Hematol
; 98(12): E357-E359, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665761
15.
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Am J Hematol
; 97(9): 1127-1134, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702875
16.
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
Am J Hematol
; 96(11): 1450-1460, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34390506
17.
Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease.
Br J Haematol
; 189(6): 1204-1209, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32030737
18.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Blood
; 141(9): 1087-1091, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574363
19.
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant.
Haematologica
; 109(2): 689-692, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706335
20.
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
Haematologica
; 109(1): 187-292, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534525